Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kelly Desimone

Optometrist, Vision Therapy Phoenix, AZ Doctor of Optometry

NPI 1164572970 CMS profile 1051297

15725 South 46Th St, Suite 112, Phoenix, AZ 85048

Open in the dashboard

General payments

$2,986

99 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kelly Desimone of Phoenix, AZ is reported in the CMS Open Payments database as having received $2,986 across 99 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Optometrist, Vision Therapy profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $206 5
2024 General $148 6
2023 General $282 9
2022 General $674 22
2021 General $615 20
2020 General $458 18
2019 General $602 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kelly Desimone
  • Optometrist, Vision Therapy median
  • Middle half of Optometrist, Vision Therapy
  • National median

In program year 2025, general payments to Kelly Desimone were reported at $206. Among 159 Optometrist, Vision Therapy profiles paid that year, the median was $172 and the middle half received between $65 and $349.

Show as a table
Year Kelly Desimone Optometrist, Vision Therapy median Middle half National median
2019 $602 $149 $42–$361 $163
2020 $458 $59 $20–$146 $114
2021 $615 $114 $43–$217 $132
2022 $674 $130 $46–$350 $149
2023 $282 $153 $70–$363 $160
2024 $148 $157 $71–$362 $164
2025 $206 $172 $65–$349 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Johnson & Johnson Vision Care, Inc. $976 33 payments
  2. CooperVision Inc. $521 14 payments
  3. Bausch & Lomb, a division of Bausch Health US, LLC $497 15 payments
  4. Alcon Vision LLC $250 12 payments
  5. Visioneering Technologies, Inc. $199 6 payments
  6. Bausch & Lomb Americas Inc. $182 4 payments
  7. Glaukos Corporation $106 1 payment
  8. Tarsus Pharmaceuticals, Inc. $77 3 payments
  9. AbbVie, Inc. $41 2 payments
  10. Kala Pharmaceuticals, Inc. $38 2 payments
  11. Other $99 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,986 99 payments
Products named General payments · program years 2019–2025
  1. Acuvue $896 29 payments
  2. INFUSE $322 6 payments
  3. MiSight Contact Lens $202 7 payments
  4. MyDay Contact Lens $162 4 payments
  5. ULTRA $142 3 payments
  6. Clariti Contact Lens $139 2 payments
  7. BIOTRUE ONE DAY $120 2 payments
  8. BIOTRUE $109 1 payment
  9. iStent inject W $106 1 payment
  10. BTOD $101 6 payments
  11. Other $652 33 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

99 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist, Vision Therapy in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record